药物检测市场 - 全球产业规模、份额、趋势、机会及预测（按产品、样本、药物类型、最终用户、地区和竞争格局划分，2021-2031年）

全球药物检测市场预计将从 2025 年的 155.6 亿美元成长到 2031 年的 212.6 亿美元，复合年增长率为 5.34%。

该行业利用技术检体尿液、毛髮、口腔液和血液等生物样本，以识别非法药物或其代谢物。推动该行业成长的关键因素包括政府对职场安全的严格监管以及全球药物滥用问题的日益严重，这些因素都要求进行严格的筛检以最大程度地降低职业风险。根据美国国家安全委员会2024年的数据，78%的受访雇主对职场阿片类药物使用的影响表示担忧，这凸显了製定有效筛检方案以确保工作安全和降低责任风险的紧迫性。

然而，由于隐私权和先前受管制物质（尤其是大麻）合法化方面的复杂监管环境，市场扩张面临许多障碍。不同司法管辖区的法律差异给跨国公司带来了沉重的合规负担，迫使它们限制检测通讯协定的范围。这种法律碎片化阻碍了标准化全球检测政策的实施，并限制了某些地区检测服务提供者的潜在收入成长，因为在这些地区，员工隐私保护优先于安全筛检措施。

市场驱动因素

全球非法药物使用量的上升是药物检测市场的主要动力。不断攀升的药物滥用率迫使公共卫生机构加强筛检工作，以追踪成瘾趋势。这一激增也包括合成鸦片类药物的氾滥，因此需要开发适应性强的毒理学检测方法来检测新型化合物。根据联合国毒品犯罪防制署（UNODC）于2024年6月发布的《2024年世界毒品报告》，到2022年，全球吸毒者人数将达到2.92亿，比过去十年增长20%。不断扩大的吸毒者群体直接推动了康復计划和法律调查所需的临床检测量。

此外，政府对职场药物筛检的严格规定也是主要驱动因素，尤其是在安全至关重要的行业。在运输和製造业等行业，监管机构正在执行严格的通讯协定以确保员工的适任性，并强制要求进行常规的入职前筛检以避免法律责任。根据Quest Diagnostics于2024年5月发布的“药物检测指数”，2023年美国普通劳动者的吸食大麻检测率上升了4.7%，迫使雇主维持严格的检测标准。此外，执法资料库也为市场提供了支援。美国联邦汽车运输安全管理局（FMCSA）报告称，2024年约有16.4万名商业驾驶人因违反毒品法规而被吊销驾照，这凸显了持续监控的重要性。

市场挑战

关于隐私权和合法化大麻的复杂监管环境，对全球药物检测市场的成长构成了重大障碍。随着各地推出法律保护非工作时间使用大麻并严格执行资料隐私保护，跨国公司面临合规环境的碎片化。这种法律上的零碎化迫使企业放宽筛检通讯协定，以避免诉讼和就业歧视指控。因此，许多雇主选择将大麻排除在标准检测项目之外，这直接降低了依赖综合多项筛检的检测服务提供者的收入潜力。

此外，联邦安全法规与州级合法化政策之间的不一致造成了严重的营运摩擦，尤其是在安全至关重要的行业。雇主必须在职业安全的重要性与劳动力萎缩和法律责任之间寻求平衡，这往往导致检测频率和范围的降低。这种不愿实施严格筛检计画的做法限制了市场规模，并阻碍了标准化全球政策的实施。 2024年，美国交通运输研究所（ATRI）分析了联邦数据，发现国家药物资讯交换中心约60%的阳性检测结果是由于违反大麻相关规定造成的，这凸显了不断发展的合法化趋势与既定的职场安全要求之间存在的严重衝突。

市场趋势

随着雇主寻求防止检体篡改并提高采集效率，口腔液检测的快速普及正在迅速改变市场格局。该方法之所以日益流行，是因为它允许在不侵犯隐私的情况下进行检体采集，从而直接应对日益严重的候选人身份欺诈和尿液检查欺诈问题。此外，在安全关键型职业中，传统方法容易被窜改，因此需要更严格的检验流程，这也进一步推动了这项转变。根据HireRight于2025年6月发布的《2025年全球基准报告》，六分之一的受访者表示在招募过程中遭遇过身分欺诈，这推动了对口腔液分析等防篡改解决方案的需求。

同时，随着员工药物使用模式的改变，包括标准五项检测无法检出的合成鸦片类药物，多项药物筛检能力的广泛应用变得日益重要。数据显示，员工在通过初次筛检后復吸率居高不下，促使各机构扩大检测通讯协定，将Fentanyl等化合物纳入其中。这种转变在入职前检测和在职检测结果的差异上尤其明显，因此有必要在随机检测项目中扩大监测范围。 Quest Diagnostics 在 2025 年 9 月发布的《药物检测指数》中指出，随机检测中普通员工Fentanyl的阳性率比入职前筛检高出 707%，凸显了全面多项药物检测的迫切需求。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球药物检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（耗材、设备、快速检测设备、服务）
  • 检体类型（尿液检体、口腔液检体、毛髮检体、其他）
  • 依药物类型（酒精、大麻/毒品、古柯碱、鸦片类药物、安非他命和甲基安非他命、LSD、其他）
  • 依最终使用者（药物检测实验室、职场、医院等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美药物检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲药物检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区药物检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲药物检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲药物检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球药物检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Abbott
• Siemens
• Thermo Fisher Scientific
• Quest Diagnostics
• LabCorp
• Roche
• Hologic
• Alere
• Danaher Corporation
• OraSure Technologies

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Drug Testing Market is projected to expand from USD 15.56 Billion in 2025 to USD 21.26 Billion by 2031, registering a CAGR of 5.34%. This industry sector involves the technical analysis of biological specimens, such as urine, hair, oral fluid, and blood, to identify illicit substances or their metabolites. Key drivers supporting this growth include strict government regulations concerning workplace safety and the increasing global prevalence of substance abuse, which demands rigorous screening to minimize occupational risks. Data from the National Safety Council in 2024 indicates that 78% of surveyed employers are concerned about opioid use affecting their workplace, underscoring the critical need for effective screening programs to ensure operational safety and reduce liability.

However, market expansion faces a significant hurdle due to the complex regulatory landscape regarding privacy rights and the legalization of previously controlled substances, especially cannabis. Varying laws across different jurisdictions create substantial compliance burdens for multinational organizations, often compelling them to limit the scope of their testing protocols. This legal fragmentation hinders the implementation of standardized global testing policies, thereby restricting potential revenue growth for testing providers in specific regions where employee privacy protections supersede safety screening measures.

Market Driver

The rising global prevalence of illicit drug consumption acts as a primary catalyst for the drug testing market. As substance abuse rates increase, public health organizations are compelled to enhance screening initiatives to track addiction trends. This surge includes the spread of synthetic opioids, requiring adaptable toxicological analysis to detect emerging compounds. The United Nations Office on Drugs and Crime reported in its June 2024 'World Drug Report 2024' that the number of people using drugs globally reached 292 million in 2022, a 20 percent rise over the previous decade. This growing user base directly drives the volume of clinical tests needed for rehabilitation programs and legal investigations.

Additionally, the implementation of stringent government mandates for workplace drug screening serves as a major driver, particularly in safety-sensitive industries. Regulatory bodies enforce rigorous protocols to ensure employee fitness in sectors like transportation and manufacturing, necessitating routine pre-employment screening policies to mitigate liability. In May 2024, Quest Diagnostics' 'Drug Testing Index' noted a 4.7% increase in the marijuana positivity rate within the general United States workforce in 2023, forcing employers to maintain vigilant testing standards. The market is further supported by enforcement databases; the Federal Motor Carrier Safety Administration reported in 2024 that approximately 164,000 commercial drivers remained in prohibited status due to drug violations, highlighting the reliance on continuous monitoring.

Market Challenge

The intricate regulatory landscape regarding privacy rights and cannabis legalization presents a formidable barrier to the growth of the Global Drug Testing Market. As jurisdictions increasingly enact laws protecting off-duty cannabis use and enforcing strict data privacy, multinational corporations encounter a fragmented compliance environment. This legal patchwork forces organizations to dilute their screening protocols to avoid litigation and hiring discrimination claims. Consequently, many employers are choosing to exclude marijuana from standard testing panels, which directly reduces the revenue potential for testing providers dependent on comprehensive multi-panel screenings.

Furthermore, the misalignment between federal safety mandates and state-level legalization creates significant operational friction, particularly in safety-sensitive industries. Employers must balance the imperative of occupational safety against a shrinking labor pool and legal liability, often resulting in reduced testing frequency or scope. This hesitation to implement rigorous screening programs stifles market volume and complicates the adoption of standardized global policies. In 2024, the American Transportation Research Institute analyzed federal data and found that marijuana violations accounted for approximately 60% of all positive drug tests in the national clearinghouse, highlighting the severe conflict between evolving legalization trends and established workplace safety requirements.

Market Trends

The Accelerated Adoption of Oral Fluid Testing is rapidly reshaping the market as employers aim to mitigate specimen tampering and improve collection efficiency. This method is increasingly favored for enabling observed sample collection without violating privacy, thereby directly addressing the growing challenge of candidate identity fraud and cheating during urine screenings. The transition is further supported by the need for more robust verification processes in safety-sensitive roles where traditional methods may be vulnerable to subversion. According to HireRight's '2025 Global Benchmark Report' in June 2025, one in six respondents reported that their business experienced identity fraud during the hiring process, driving the demand for tamper-evident solutions like oral fluid analysis.

Simultaneously, the Proliferation of Multi-Panel Screening Capabilities is becoming critical as workforce drug use patterns evolve to include synthetic opioids not detected by standard five-panel tests. Organizations are expanding their testing protocols to include compounds such as fentanyl, driven by data revealing that employees often resume substance use after passing initial screenings. This shift is particularly evident in the disparity between pre-employment and active-duty test results, necessitating broader surveillance panels for random testing programs. Quest Diagnostics reported in the September 2025 '2025 Drug Testing Index' that the positivity rate for fentanyl in the general workforce was 707% higher in random drug tests compared to pre-employment screenings, highlighting the urgent operational requirement for comprehensive multi-panel diagnostics.

Key Market Players

• Abbott
• Siemens
• Thermo Fisher Scientific
• Quest Diagnostics
• LabCorp
• Roche
• Hologic
• Alere
• Danaher Corporation
• OraSure Technologies

Report Scope

In this report, the Global Drug Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Drug Testing Market, By Product

• Consumables
• Instruments
• Rapid Testing Devices
• Services

Drug Testing Market, By Sample

• Urine Samples
• Oral Fluid Samples
• Hair Samples
• Other

Drug Testing Market, By Drug Type

• Alcohol
• Cannabis/Marijuana
• Cocaine
• Opioids
• Amphetamine & Methamphetamine
• LSD
• Others

Drug Testing Market, By End User

• Drug Testing Laboratories
• Workplaces
• Hospitals
• Others

Drug Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Drug Testing Market.

Available Customizations:

Global Drug Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Drug Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Consumables, Instruments, Rapid Testing Devices, Services)
  • 5.2.2. By Sample (Urine Samples, Oral Fluid Samples, Hair Samples, Other)
  • 5.2.3. By Drug Type (Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD, Others)
  • 5.2.4. By End User (Drug Testing Laboratories, Workplaces, Hospitals, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Drug Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Sample
  • 6.2.3. By Drug Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Drug Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Sample
      • 6.3.1.2.3. By Drug Type
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Drug Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Sample
      • 6.3.2.2.3. By Drug Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Drug Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Sample
      • 6.3.3.2.3. By Drug Type
      • 6.3.3.2.4. By End User

7. Europe Drug Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Sample
  • 7.2.3. By Drug Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Drug Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Sample
      • 7.3.1.2.3. By Drug Type
      • 7.3.1.2.4. By End User
  • 7.3.2. France Drug Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Sample
      • 7.3.2.2.3. By Drug Type
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Drug Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Sample
      • 7.3.3.2.3. By Drug Type
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Drug Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Sample
      • 7.3.4.2.3. By Drug Type
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Drug Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Sample
      • 7.3.5.2.3. By Drug Type
      • 7.3.5.2.4. By End User

8. Asia Pacific Drug Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Sample
  • 8.2.3. By Drug Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Drug Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Sample
      • 8.3.1.2.3. By Drug Type
      • 8.3.1.2.4. By End User
  • 8.3.2. India Drug Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Sample
      • 8.3.2.2.3. By Drug Type
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Drug Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Sample
      • 8.3.3.2.3. By Drug Type
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Drug Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Sample
      • 8.3.4.2.3. By Drug Type
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Drug Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Sample
      • 8.3.5.2.3. By Drug Type
      • 8.3.5.2.4. By End User

9. Middle East & Africa Drug Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Sample
  • 9.2.3. By Drug Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Drug Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Sample
      • 9.3.1.2.3. By Drug Type
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Drug Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Sample
      • 9.3.2.2.3. By Drug Type
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Drug Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Sample
      • 9.3.3.2.3. By Drug Type
      • 9.3.3.2.4. By End User

10. South America Drug Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Sample
  • 10.2.3. By Drug Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Drug Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Sample
      • 10.3.1.2.3. By Drug Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Drug Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Sample
      • 10.3.2.2.3. By Drug Type
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Drug Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Sample
      • 10.3.3.2.3. By Drug Type
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Drug Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Siemens
• 15.3. Thermo Fisher Scientific
• 15.4. Quest Diagnostics
• 15.5. LabCorp
• 15.6. Roche
• 15.7. Hologic
• 15.8. Alere
• 15.9. Danaher Corporation
• 15.10. OraSure Technologies

16. Strategic Recommendations

17. About Us & Disclaimer